Cost-effectiveness of reflex laboratory-based cryptococcal antigen screening for the prevention and treatment of cryptococcal meningitis in Botswana. by Tenforde, Mark W et al.
LSHTM Research Online
Tenforde, Mark W; Muthoga, Charles; Callaghan, Andrew; Ponetshego, Ponego; Ngidi, Julia;
Mine, Madisa; Jordan, Alexander; Chiller, Tom; Larson, Bruce A; Jarvis, Joseph N; (2019) Cost-
effectiveness of reflex laboratory-based cryptococcal antigen screening for the prevention and treat-
ment of cryptococcal meningitis in Botswana. Wellcome Open Research, 4. p. 144. DOI:
https://doi.org/10.12688/wellcomeopenres.15464.1
Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4654660/
DOI: https://doi.org/10.12688/wellcomeopenres.15464.1
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
 Open Peer Review
Any reports and responses or comments on the
article can be found at the end of the article.
RESEARCH ARTICLE
Cost-effectiveness of reflex laboratory-based cryptococcal
antigen screening for the prevention and treatment of
 cryptococcal meningitis in Botswana [version 1; peer review: 1
approved]
Mark W. Tenforde ,     Charles Muthoga , Andrew Callaghan ,
       Ponego Ponetshego , Julia Ngidi , Madisa Mine , Alexander Jordan ,
   Tom Chiller , Bruce A. Larson , Joseph N. Jarvis 3,4,8*
University of Washington School of Medicine, Seattle, Washington, 98195, USA
University of Washington School of Public Health, Seattle, WA, 98195, USA
Botswana-UPenn Partnership, Gaborone, Botswana
Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
National Health Laboratory, Gaborone, Botswana
Centers for Disease Controls and Prevention, Atlanta, Georgia, 30329-4018, USA
Boston University School of Public Health, Boston, MA, 02118, USA
London School of Hygiene & Tropical Medicine, London, UK
 Equal contributors
Abstract
Cryptococcal antigen (CrAg) screening for antiretroviralBackground: 
therapy (ART)-naïve adults with advanced HIV/AIDS can reduce the
incidence of cryptococcal meningitis (CM) and all-cause mortality. We
modeled the cost-effectiveness of laboratory-based “reflex” CrAg screening
for ART-naïve CrAg-positive patients with CD4<100 cells/µL (those
currently targeted in guidelines) and ART-experienced CrAg-positive
patients with CD4<100 cells/µL (who make up an increasingly large
proportion of individuals with advanced HIV/AIDS).
A decision analytic model was developed to evaluate CrAgMethods: 
screening and treatment based on local CD4 count and CrAg prevalence
data, and realistic assumptions regarding programmatic implementation of
the CrAg screening intervention. We modeled the number of CrAg tests
performed, the number of CrAg positives stratified by prior ART experience,
the proportion of patients started on pre-emptive antifungal treatment, and
the number of incident CM cases and CM-related deaths. Screening and
treatment costs were evaluated, and cost per death or disability-adjusted
life year (DALY) averted estimated.
We estimated that of 650,000 samples undergoing CD4 testingResults: 
annually in Botswana, 16,364 would have a CD4<100 cells/µL and receive
a CrAg test, with 70% of patients ART-experienced at the time of screening.
Under base model assumptions, CrAg screening and pre-emptive
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 Under base model assumptions, CrAg screening and pre-emptive
treatment restricted to ART-naïve patients with a CD4<100 cells/µL
prevented 20% (39/196) of CM-related deaths in patients undergoing CD4
testing at a cost of US$2 per DALY averted. Expansion of preemptive
treatment to include ART-experienced patients with a CD4<100 cells/µL
resulted in 55 additional deaths averted (a total of 48% [94/196]) and was
cost-saving compared to no screening. Findings were robust across a
range of model assumptions.
Reflex laboratory-based CrAg screening for patients withConclusions: 
CD4<100 cells/µL is a cost-effective strategy in Botswana, even in the
context of a relatively low proportion of advanced HIV/AIDS in the overall
HIV-infected population, the majority of whom are ART-experienced.
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Introduction
Cryptococcal meningitis (CM) is a leading cause of mortality 
in people living with HIV/AIDS (PLWH) worldwide, causing 
an estimated 15% of HIV deaths1. HIV-associated CM predomi-
nantly occurs in the setting of advanced HIV disease, typically 
at a CD4 T-cell count <100 cells/µL2. In patients with advanced 
HIV initiating antiretroviral therapy (ART), detection of cryp-
tococcal antigen (CrAg) in the blood is highly predictive of 
subsequent CM3, with clinical symptoms usually developing 
within a few weeks3,4. CrAg screening with pre-emptive flucona-
zole therapy in CrAg-positive ART-naïve adults (without symp-
toms/signs of CM) has been shown to reduce all-cause mortality 
and is recommended by the World Health Organization (WHO) 
in adults starting ART with a CD4 <100 cells/µL5,6.
Botswana, a country of approximately 2.3 million with a 2017 
adult HIV prevalence of 23%7, has a mature HIV program pro-
viding free ART to citizens since 2002. Despite ART scale-up, 
advanced HIV/AIDS and CM remain common with almost 400 
confirmed cases diagnosed per year in 2013 and 20142,8,9. In 
2016, national HIV guidelines first recommended CrAg 
screening in ART-naïve, CrAg-positive patients with a CD4 
<100 cells/µL10. For CrAg-positive ART-naïve patients, flu-
conazole 1200 mg/day for 2 weeks, then 800 mg/day for 
8 weeks with ART initiation, then 200 mg/day until CD4 recov-
ers to >200 cells/µL for at least 6 months is recommended. 
Currently, “reflex” screening (screening of any sample sent 
for CD4 testing below the CD4 count threshold) is conducted 
at the Botswana-Harvard HIV Reference Laboratory (BHHRL), 
which performs most CD4 testing in the urban Gaborone 
region. The cost-effectiveness of CrAg screening has not been 
evaluated in Botswana.
In addition, with reflex CrAg screening, a new question has 
arisen: how to manage ART-experienced, CrAg-positive patients. 
With a laboratory-based, reflex CrAg screening program, a 
CrAg test is performed following all CD4 results <100 cells/µL. 
Since the lab does not know who is treatment-naïve and who is 
not, both ART-naïve and -experienced patients are CrAg screened. 
Previous models assumed that all or most CrAg-screened 
patients are ART-naïve11–13, and therefore only focused on ART-
naïve patients. However, in Botswana as well as elsewhere in 
sub-Saharan Africa, over half of CM cases now occur in ART- 
experienced patients14–16, and reflex screening where CD4 moni-
toring is conducted is now identifying an important number of 
ART-experienced and CrAg-positive patients. This popula-
tion represents a mix of individuals: 1) those recently started on 
ART without baseline CD4 and CrAg screening results following 
adoption of the HIV “test-and-treat” strategy17; 2) those on ART 
but with treatment failure; and 3) those started on ART with 
subsequent ART default re-engaging in ART care. Current 
CrAg screening guidelines do not address management of this 
growing population, although there is a highly plausible benefit 
of treating these CrAg-positive patients.
The primary aim of our study was to model the cost-effectiveness 
of CrAg screening and targeted pre-emptive fluconazole treat-
ment in Botswana using different screening and treatment policies. 
A decision analytic model was developed based on prior 
models13,18, with local CD4 distribution8, CrAg prevalence19, 
treatment outcomes14, ART status, and costing data. Two related 
policies are evaluated. For Policy 1, based on current guide-
lines, we modeled reflex CrAg screening for any patient with a 
CD4 <100 cells/µL and then pre-emptive treatment only for the 
ART-naïve patients10. The model for Policy 1 is used to estimate 
national costs for screening and the cost-effectiveness of this 
screening policy compared to no screening based on the cost 
per death averted and the cost per disability-adjusted life year 
(DALY). For Policy 2, we extend the analysis of Policy 1 to 
also incorporate pre-emptive treatment for ART-experienced 
individuals identified as part of reflex screening. We evaluated 
these models under a range of assumptions.
Methods
Overview
Our models use CD4 count distribution and CrAg prevalence 
data from the BHHRL in Gaborone, including data from a 
completed CrAg screening prevalence study conducted 
2015–2016 and a second cohort from January 2018 through 
January 201919. Both studies received ethical approvals from the 
Botswana Health Research and Development Committee (HRDC) 
[HPDME 13/18/1] and the University of Pennsylvania Institu-
tional Review Board (#827814), along with this cost-effectiveness 
analysis. CrAg testing is performed using the highly accurate 
CrAg lateral flow assay (LFA) [IMMY, Norman, OK]20, assumed 
for the analysis to be 100% sensitive and specific. Approximately 
65,000 CD4 tests are performed annually at the BHHRL in 
35,000 unique patients. With an estimated population of 370,000 
adults in Botswana living with HIV, most of whom know their 
HIV-status and have engaged with HIV-care services21,22, this 
covers nearly 10% of the adult HIV-positive population in 
Botswana. We therefore chose to start with a model of 650,000 
CD4 tests performed annually on a population of 350,000 adults 
to provide an estimate of the annual cost and impact of CrAg 
screening implementation at a national level. Our models 
include two components: 1) A reflex CrAg screening module; 
and 2) a treatment module.
Screening module for the current policy (Policy 1)
The screening model estimates the proportion of patients 
who receive CD4 testing with a CD4 count <100 cells/µL, the 
proportion with prior evidence of ART use, the proportion CrAg-
positive, the proportion who are preemptive treatment-eligible, 
and the proportion of these patients who remain asymptomatic 
and are targeted for preemptive therapy or are diagnosed with 
CM on urgent clinic follow-up after a positive CrAg test. The 
model includes imperfect “real-world” implementation, so that a 
proportion of eligible patients may not receive CrAg screening 
or are screened but do not receive timely evaluation. Figure 1 
summarizes the screening model for Policy 1 (CrAg screen-
ing if CD4 <100 cells/µL), and Table 1 provides sources for 
parameter estimates. A full description of model estimates and 
data sources is available as Underlying data23.
In Figure 1, 2.65% of CD4 samples from clinics have a CD4 
count <100 cells/µL (based on estimates from 2015–2017), with 
a local CrAg prevalence of 4.6% at CD4 <100 cells/µL in non-
hospitalized patients19. Only 30% of patients have no prior 
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Figure 1. Flowcharts of screening module. Panel 0 describes the proportion of CD4 tests with a CD4 <100 cells/µL (target population 
for CrAg screening per national Botswana guidelines). (a) Outcomes for pre-ART, CrAg-positive patients eligible for screening but in whom 
screening is not conducted. (b) Outcomes for pre-ART patients who screen CrAg-positive but do no return for urgent follow-up. (c) Outcomes 
for pre-ART patients who screen CrAg-positive and return for urgent follow-up. (d) Outcomes for ART-experienced, CrAg-positive patients 
eligible for screening but in whom screening is not conducted. (e) Outcomes for ART-experienced patients who screen CrAg-positive but do 
no return for urgent follow-up. (f) Outcomes for ART-experienced patients who screen CrAg-positive and return for urgent follow-up.
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Table 1. Key parameters, estimates, and sources of data for base model.
Screening Module
Parameter CD4 <100 cells/µl Source(s)
% within CD4 strata 2.65% BHHRL data
CrAg prevalence within CD4 strata 
(outpatient), %
4.6% 19,24
Prior CM among screened CrAg+, % 25% 19
High CrAg titer (≥1:180), % 59% 19
Pre-ART of CrAg+, % 30% Local cohort8
Return quickly enough of CrAg+, % 75% Assumption
Treatment Module
Parameter CD4 <100 cells/µl Source(s)
Hospitalized if missed CrAg+ and develops 
CM, %
80% Assumption
                        10-week CM mortality 50% 14 
                               CM relapse 17% 14
High CrAg titer and fail pre-emptive therapy 
(if receive fluconazole)
20% 25,26
Low CrAg titer and fail pre-emptive therapy 
(if receive fluconazole)
5% 25,26
Hospitalized if fail pre-emptive therapy and 
develop CM
90% Assumption
                        10-week mortality 25% 25
                               CM relapse 17% 14
Hospitalized if diagnosed with CM at urgent 
follow-up visit 
100% Assumption
                        10-week mortality 25% 25
                               CM relapse 17% 14
BHHRL = Botswana-Harvard HIV Reference Laboratory; CM = cryptococcal meningitis
viral load testing documented in the national electronic medi-
cal record (EMR), Integrated Patient Management System. As 
baseline viral load testing is not performed in Botswana, with ini-
tial viral load testing 3–6 months after starting ART10, any client 
with viral load testing prior to CrAg screening can be assumed 
to be ART-experienced. Further, of CrAg-positive samples 
approximately 25% are assumed to be from patients with prior 
treated cryptococcal disease, which results in a persistently 
positive test result. These patients are not targeted for pre-emptive 
therapy. The remaining 75% of CrAg-positive patients are poten-
tially eligible for pre-emptive fluconazole.
We used local CrAg titer data to estimate the risk of 
ART-naïve CrAg-positive patients progressing to CM19. A high 
CrAg titer (>1:160) is associated with a high risk of CM with-
out pre-emptive treatment in ART-naïve patients25,27. From local 
data, 59% of CrAg-positive patients with a CD4 <100 cells/µL 
have a high CrAg titer. A lumbar puncture is offered to all CrAg-
positive patients evaluated for pre-emptive therapy to rule out 
prevalent CM, as up to one-third of even relatively asympto-
matic CrAg-positive patients have prevalent meningitis diagnosed 
when evaluated by lumbar puncture (LP) and cerebrospinal fluid 
(CSF) testing25,27. As LP refusal is common28, we estimate that 
only 25% of patients consent to an LP. A total of 85% of high-
titer and 15% of low-titer patients who undergo LP are diagnosed 
with prevalent CM and hospitalized25. The remaining CrAg- 
positive patients (i.e. those who did not undergo LP or had 
negative CSF testing) are targeted for pre-emptive fluconazole.
A proportion of CrAg-positive patients who should receive 
CrAg screening are not tested (5%), e.g. due to laboratory error 
or CrAg assay stockout. Without CrAg testing and pre-emptive 
fluconazole, these patients are at an high risk of incident CM, 
with risk influenced by a patient’s CrAg titer and how quickly 
ART is initiated3,25,29. Of screened CrAg-positive patients, an 
estimated 25% with CD4 <100 cells/µL do not return to clinic 
quickly for evaluation and initiation of pre-emptive flucona-
zole and/or LP evaluation; these patients are also at a high risk 
of progression to CM.
Treatment module for the current policy (Policy 1)
The treatment module estimates outcomes for (a) patients 
who should receive CrAg screening but do not and progress to 
CM, (b) those who receive screening but progress to CM without 
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urgent follow-up and pre-emptive therapy, (c) those diagnosed 
with CM at the initial urgent follow-up visit, and (d) those 
who start but “fail” pre-emptive treatment, developing CM. 
Flowcharts for the treatment module are shown in Figure 2, 
and sources for estimates detailed in the Underlying data23.
For ART-naïve CrAg-positive patients, outcomes of pre- 
emptive treatment are derived from local estimates and a pub-
lished systematic review19,29; we estimate that 20% of high-titer 
patients and 5% of low-titer patients started on pre-emptive fluco-
nazole will fail pre-emptive fluconazole and go on to develop CM.
For patients who progress to CM, case-fatality rates are derived 
from local data14. Ten-week mortality for patients with a 
CD4 <100 cells/µL hospitalized for cryptococcal meningitis and 
treated with amphotericin B-based induction therapy is estimated 
to be 50%, with 17% of survivors experiencing relapse. CrAg- 
positive patients who are diagnosed with early CM on urgent 
follow-up or hospitalized after failing pre-emptive fluconazole 
are assumed to have a lower 10-week mortality (25% instead of 
50% for those missed and not started on pre-emptive treatment) 
based on regional data25, with early recognition of infection and 
timely initiation of antifungal treatment associated with better 
survival. In our models, we assume that a minority of patients 
(20%) with incident CM die at home without being diagnosed, 
with a lower proportion who start on pre-emptive fluconazole 
(10%) or are diagnosed with CM at their initial follow-up (0%).
Screening and treatment modules extending treatment to 
ART-experienced CrAg-positive clients (Policy 2)
In Policy 2, in addition to ART-naïve patients we model preemp-
tive treatment for ART-experienced CrAg-positive patients 
with a CD4 <100 cells/µL. From 2018-2019 cohort data, approxi-
mately 70% of patients with a CD4 <100 cells/µL had docu-
mented HIV viral load testing by the time of CrAg screening 
indicating a history of ART use. Some of these ART-experienced 
patients have experienced ART failure or default and are assumed to 
be at high risk for progression to CM, whereas others are recently 
started on ART with HIV viral suppression awaiting immune 
recovery and assumed to be at comparatively lower risk for pro-
gression to CM. For CrAg-positive patients with ART treat-
ment failure, without preemptive fluconazole therapy we assume 
a 90% risk of progression to CM based on anticipated delays in 
ART regimen change and prolonged immunosuppression. For 
CrAg-positive patients who have defaulted ART and are now 
re-engaging in care, we assume a 50% risk of progression 
to CM without preemptive fluconazole therapy, or approxi-
mately twice as high as the published risk of CM progression in 
CrAg-positive ART-naïve patients who do not receive preemp-
tive therapy3,29. We estimate a higher risk compared to 
ART-naïve patients starting ART because of a greater likelihood 
of worse adherence or default in this population with previous 
ART default. For patients who recently started on ART with 
good virological response who are awaiting CD4 recovery, we 
assume a 10% risk of progression to CM without preemptive 
Figure 2. Flowcharts of treatment module. (a) Outcomes for CrAg-positive patients with missed CrAg screening who develop cryptococcal 
meningitis. (b) Outcomes for ART-naïve, CrAg-positive patients who are identified for pre-emptive treatment but do not receive it. (c) Outcomes 
for ART-naïve, CrAg-positive patients who receive pre-emptive treatment. (d) Outcomes for ART-experienced, CrAg-positive patients who 
receive or do not receive pre-emptive treatment. (e) Outcomes for CrAg-positive patients diagnosed with cryptococcal meningitis on urgent 
follow-up.
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therapy, about half the risk in CrAg-positive ART-naïve patients 
starting ART who do not receive preemptive therapy3,29. As 
the median time to CM diagnosis is approximately 5 weeks in 
CrAg-positive patients newly starting ART without preemp-
tive therapy and incidence of CM falls rapidly following ART 
initiation3,4, this estimate accounts for the fact that these 
patients have already been on ART for several weeks or months 
without a diagnosis of CM and therefore are likely at a lower 
risk of progression.
From 2018–2019 local cohort data, 40% of ART-experienced 
patients with a CD4 <100 cells/µL had a suppressed HIV viral 
load within 3 months prior to the date of CrAg screening and are 
assumed to fit into this lower-risk category (10% for CrAg- 
positive patients without preemptive therapy). The remaining 
60% without recent HIV viral load testing or a recent 
non-suppressed HIV viral load are assumed to be at higher risk 
for CM progression due to ART default (50% risk in CrAg- 
positive without preemptive therapy) or treatment failure (90% 
risk in CrAg-positive without preemptive therapy). About half of 
these patients (30%) had no viral load testing in the previous 
6 months and are assumed to have defaulted, whereas the other 
half (30%) had viral load testing within 6 months but with 
their last viral load unsuppressed and are assumed to have 
experienced treatment failure.
For ART-experienced patients, given lack of published out-
comes data in this population we assume that there is a 75% 
reduction in the risk of progression to CM with pre-emptive 
therapy. In the base model, we also assume that the same propor-
tion of ART-experienced clients who are seen at urgent follow-up 
are diagnosed with CM by lumbar puncture as with ART-naïve 
clients. Screening and treatment flow diagrams are shown in 
Figure 1 and Figure 2 for Policy 2.
CrAg screening and treatment unit costs
The costs of CrAg screening implementation and CM treat-
ment are estimated from a provider-perspective using 2018 local 
supply costs from Botswana Central Medical Stores (CMS) 
for most parameter estimates (Table 2 and Underlying data23). 
Costs in Botswana Pula were converted to United States dol-
lars (US$) using mid-2018 exchange rates (10.61 Pula to US$1, 
which has remained largely unchanged). For CrAg screening, 
the cost per CrAg test is estimated at 50 Pula (US$4.71); to the 
wholesale price (~US$2), we factor in additional mark-ups from 
local distributors, shipment, and laboratory personnel costs. 
Table 2. Included cost estimates for CrAg screening and pre-emptive treatment and for 
cryptococcal meningitis treatment.
CrAg screening and pre-emptive therapy *
Parameter Estimate (USD) Source(s)
CrAg LFA $4.71 IMMY wholesale plus 
additional costs
Pre-emptive fluconazole
1200 mg/day x2 weeks
800 mg/day x8 weeks
200 mg/day x26 weeks
$0.51 / 200 mg tablet
x 490 tablets = $247.54
CMS;
proportion with treatment 
failure or partial adherence
Urgent return evaluation $18.85 Assumption
Treatment Module *
Parameter Estimate (%) Source(s)
Hotel costs
                 17-day hospital stay
$188.51 / hospital day 14,30
Hospital drug and procedure costs
     Including 14 days AmBd and 
FLU, 2 lumbar punctures
$202.24 (survives), 
$151.68 (dies)
CMS; 14
Post-admission costs
     FLU consolidation/maintenance,
                 Extra clinic visit
$226.37 CMS
Laboratory costs
                 2 FBC, 4 U/E, 1 ALT
$71.00 BHHRL; 6
* See Supplementary Excel File for detailed costing estimates
ALT = alanine aminotransferase; AmBd = amphotericin B deoxycholate; BHHRL = Botswana Harvard HIV 
Reference Laboratory; CM = cryptococcal meningitis; CMS = Central Medical Stores; FBC = full blood 
count; FLU = fluconazole; KCl = potassium choloride; Mg = magnesium supplementation; NS = normal 
saline; U/E = urea and electrolyte testing; WHO = World Health Organization
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Fluconazole is relatively expensive in Botswana (at ~US$0.50 
per 200 mg tablet through CMS) compared to other countries 
in the region and we assumed procurement through CMS rather 
than a pharmaceutical company drug donation program. Aver-
age length of maintenance therapy is estimated at 6 months, 
assuming some incomplete adherence.
We do not have reliable local hospital “hotel” costs in Botswana 
for the treatment of CM. Therefore, WHO-CHOICE estimates 
for cost per day of hospital admission in 2008 are used assum-
ing most cases are managed at referral/teaching hospitals with 
100% occupancy and 10,000 admissions per year, and infla-
tion-adjusting for 2018 prices using International Monetary Fund 
estimates2,30,31. Length of hospital stay was estimated at 17 days 
for survivors for local data (75% of this time in those who die 
within 10 weeks)14. We assume a standard 14-day course of 
amphotericin B with high-dose fluconazole, intravenous fluid and 
electrolyte supplementation, and routine laboratory monitor-
ing. Patients who survive hospitalization receive 8 weeks of flu-
conazole consolidation and 6 months of maintenance fluconazole 
on average. Patients who die within 10 weeks of treatment 
have lower utilization of treatment, laboratory, and post- 
discharge care and fluconazole (see Underlying data23).
Outcomes
We estimate total annual costs of CrAg screening and treatment 
(both for pre-emptive fluconazole and cryptococcal meningi-
tis) from the provider perspective for each policy. Comparing 
these to a counterfactual scenario with no screening, we esti-
mate the number of cryptococcal meningitis cases averted from 
screening, number of deaths prevented, and the cost per death 
averted as the incremental cost effectiveness ratio. We also 
evaluated cost per DALY avoided. With an average age of death 
from CM of 36 years from local data14, age-specific, gender- 
averaged life expectancy of 36 additional years from 2016 WHO 
Global Health Observatory data32, and with a 3% annual dis-
count rate, we estimated 21.4 DALYs avoided per death avoided. 
We then re-evaluated models with both ART-naïve (the target 
population for CrAg screening) and ART-experienced CrAg- 
positive patients being offered pre-emptive treatment. We do 
not factor in additional costs or deaths from CM relapse as these 
are small and unlikely to have a significant public health or 
health system cost impact.
Sensitivity analyses
We performed a series of sensitivity analyses to account for 
areas of uncertainty or possible changes in CD4 testing practices. 
As Policy 2 dominated no CrAg screening and Policy 1 
(see Results), all sensitivity analyses were performed for Policy 2:
Sensitivity analysis 1: This model assumes 50% (versus 75% 
in the base model) of CrAg-positive patients return quickly for 
urgent follow-up and initiating of pre-emptive therapy with other 
parameter estimates remaining the same.
Sensitivity analysis 2: This model assumes a combined 25% risk 
of CM progression for CrAg-positive ART-experienced patients 
without pre-emptive therapy (versus 46% in the base model) 
and with no CrAg-positive ART-experienced patients diagnosed 
with CM by lumbar puncture at urgent follow-up. Other param-
eter estimates remain unchanged. This sub-analysis accounts 
for uncertainty in the benefit of preemptive therapy for CrAg- 
positive ART-experienced patients given the lack of published 
literature in this group.
Sensitivity analysis 3: This model assumes 70% of clients are 
ART-naïve and 30% ART-experienced (versus 30% and 70%, 
respectively, in the base model) with risk of progression to 
CM with and without pre-emptive therapy unchanged. The 
sub-analysis was conducted to account for potential changes in 
CD4 testing practices.
Results
Cryptococcal meningitis cases and costs without 
screening
Without CrAg screening, our base model estimates 17,225 
CD4 counts <100 cells/µL. In the base model without CrAg 
screening, 305 patients with a CD4 <100 cells/µL develop CM 
without screening, 41% (126/305) are ART-naïve, and 196 CM- 
related deaths occur, with an additional 22 relapse CM cases 
(Table 3). The number of cases is lower than the nearly 
400 CM cases microbiologically confirmed annually in 
Botswana without CrAg screening2; however, a proportion of 
patients will be diagnosed and hospitalized with CM without 
recent CD4 testing. The proportion of patients who are 
ART-naïve is consistent with local and regional estimates 
that half or more CM cases now occur in ART-experienced 
individuals14,15. The overall total cost for CM treatment is 
estimated at $851,716,
Policy 1. CrAg screening at CD4 <100 cells/µL, ART-naïve 
only
In our CD4 <100 cells/µL base model, 16,364 CrAg tests are 
performed at a cost of $77,073. Without screening, we estimate 
196 CM-related deaths annually in this CD4 <100 cells/µL 
population. For ART-naïve only, with CrAg screening and 
treatment, we estimate 39 lives saved (a 20% reduction in CM-
related deaths among those patients with CD4 testing), at a cost 
of $43 per death prevented or $2 per DALY averted (Table 4).
Policy 2. CrAg screening at CD4 <100 cells/µL, both ART-
naïve and ART-experienced
We next considered treating both ART-naïve as well as 
ART-experienced patients recognized as CrAg-positive through 
reflex screening. No additional costs are accrued for screen-
ing ART-experienced patients. Under base model assumptions, 
an additional 55 lives were saved through treatment of ART-
experienced patients (Table 5). Treatment of both ART-naïve and 
ART-experienced resulted in an overall savings of $1421 per 
death averted, or $66 per DALY averted. Policy 2 dominated 
both no screening and the Policy 1 strategy of treatment only for 
ART-naïve clients (Table 6). CrAg screening under Policy 2 
remained cost-saving across a range of scenarios (see Underlying 
data23 for results of sensitivity analyses).
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Table 3. Estimated cryptococcal meningitis cases, deaths, and costs without CrAg screening.
Population: CD4 < 100 cells/µL Results - ART-
naïve
Results - ART-
experienced Results - Total
Number 
patients
Cost for 
patients
Number 
patients
Cost for 
patients
Number 
patients
Cost for 
patients
Identified for preemptive treatment (but 
did not receive), but did not develop 
CM -- survives
0 0 0 0 0 0
Identified for preemptive treatment, 
receives treatment, survives
0 0 0 0 0 0
Not hospitalized, dies 27 0 38 0 65 0
Hospitalized, dies < 10 weeks 54 148,992 77 210,661 131 359,653
Hospital, survives maintenance 45 169,191 64 239,221 109 408,413
Hospital, CM relapse 9 34,654 13 48,997 22 83,651
Total Treatment Costs 352,837 498,879 851,716
Total Screening Costs 0 0 0
Total Costs 352,837 498,879 851,716
Total Cases 135 191 326
Total Deaths 81 115 196
ART = antiretroviral therapy; CM = cryptococcal meningitis; CrAg = cryptococcal antigen
Table 4. Estimated cryptococcal meningitis cases, deaths, and costs for CrAg screening and 
treatment of only ART-naïve (Policy 1).
Population: CD4 < 100 cells/µL
Results - ART-
naïve
Results - ART-
experienced (same 
as above with no 
screening) Results - Total
Number 
patients
Cost for 
patients
Number 
patients
Cost for 
patients
Number 
patients
Cost for 
patients
Identified for preemptive treatment 
(but did not receive), but did not 
develop CM -- survives
3 0 0 0 3 0
Identified for preemptive treatment, 
receives treatment, survives
84 22,351 0 0 84 22,351
Not hospitalized, dies 12 60 38 0 51 60
Hospitalized, dies < 10 weeks 30 82,847 77 210,661 107 293,508
Hospital, survives maintenance 38 142,912 64 239,221 101 382,133
Hospital, CM relapse 8 29,271 13 48,997 21 78,268
Total Treatment Costs 277,440 498,879 776,320
Total Screening Costs 77,073 0 77,073
Total Costs 354,513 498,879 853,393
Total Cases 88 191 279
Total Deaths 42 115 157
ART = antiretroviral therapy; CM = cryptococcal meningitis; CrAg = cryptococcal antigen
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Table 5. Estimated cryptococcal meningitis cases, deaths, and costs for CrAg screening and treatment 
of both ART-naïve and ART-experienced (Policy 2).
Population: CD4 < 100 cells/µL
Results - ART-
naïve
Results - ART-
experienced Results - Total
Number 
patients
Cost for 
patients
Number 
patients
Cost for 
patients
Number 
patients
Cost for 
patients
Identified for preemptive treatment (but 
did not receive), but did not develop 
CM -- survives
3 0 14 0 16 0
Identified for preemptive treatment, 
receives treatment, survives
84 22,351 201 53,574 285 75,925
Not hospitalized, dies 12 60 16 116 28 176
Hospitalized, dies < 10 weeks 30 82,847 44 130,742 73 213,588
Hospital, survives maintenance 38 142,912 64 150,503 102 293,415
Hosptal, CM relapse 8 29,271 13 28,486 21 57,757
Total Treatment Costs 277,440 363,421 640,861
Total Screening Costs 77,073 0 77,073
Total Costs 354,513 363,421 717,934
Total Cases 88 137 225
Total Deaths 42 59 102
ART = antiretroviral therapy; CM = cryptococcal meningitis; CrAg = cryptococcal antigen
Table 6. Incremental cost-effectiveness ratio for CrAg screening and treatment strategies.
Population: CD4 < 100 cells/µL Deaths Costs Change 
costs
Change 
deaths
DALY 
averted
Cost per 
death 
averted
Cost per 
DALY 
averted
Comments
No screening 196 851,716 n/a n/a n/a n/a n/a Initial comparison 
policy
Base Model: Screening < 100, 
preemptive txt only ART-naïve
157 853,393 1,676 -39 829 43 2 Dominates no 
screening
Base Model: Screening < 100, 
preemptive txt both ART-naïve and 
ART-experienced
102 717,934 -133,782 -94 2014 -1421 -66 Dominates Policy 
1 (compared to 
preemptive txt only 
ART naïve)
Discussion
Using robust local clinical, outcomes, and costing data, we pro-
vide the first estimates of the cost-effectiveness and impact 
of CrAg screening implementation in Botswana. This analy-
sis was intended to be pragmatic, reflecting current CD4 testing 
practices in real world settings in Botswana, a country where 
national guidelines currently recommend CD4 testing at base-
line (pre-ART), at three months, at 12 months and yearly 
thereafter for stable clients10. This strategy, coupled with adoption 
of HIV “test-and-treat”33, contributes to a growing proportion of 
ART-experienced CrAg-positive individuals recognized through 
laboratory-based reflex screening in Botswana. Existing screen-
ing guidelines and modeling studies have not considered the 
impact of this large population or benefits of pre-emptive 
treatment. As in other studies from sub-Saharan Africa11,13,18, 
we found CrAg screening in ART-naïve patients with a CD4 
<100 cells/µL to avoid a DALY for a low cost (e.g., substantially 
less than one year of ART medication costs). Targeting only 
CrAg-positive ART-naïve patients for pre-emptive therapy, 
however, had a modest public health impact, preventing only 
20% of CM-related deaths under base model assumptions. 
Additionally, treating CrAg-positive ART-experienced patients 
resulted in additional deaths prevented, and was cost-saving 
or avoided a DALY for a very low cost across a range of 
assumptions.
CD4 testing remains necessary for identifying individuals 
with advanced HIV disease (i.e. low CD4 count) and guiding 
CrAg screening and other preventive measures against com-
mon opportunistic infections. With decreased funding for CD4 
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testing and an increasing focus on HIV viral load rather than 
CD4 monitoring in patients on ART17, our findings may be less 
relevant in countries that do not support CD4 assessment fol-
lowing ART initiation. Nevertheless, in settings where post-ART 
CD4 testing is available, CD4 monitoring and CrAg screen-
ing—particularly in individuals with treatment failure or a his-
tory of default—may provide an additional public health benefit 
as the HIV epidemic matures in sub-Saharan Africa with a major-
ity of cryptococcal meningitis occurring in ART-experienced 
individuals. International guidelines should address the clinical 
management in this emerging population, and future outcomes 
research is needed to better inform the benefit of preemptive 
therapy.
Our study has a number of limitations. First, we had signifi-
cant uncertainty for a number of parameter estimates, par-
ticularly the risk of progression to cryptococcal meningitis for 
CrAg-positive individuals previously started on ART and the 
proportion of clients identified as CrAg-positive who receive 
urgent follow-up care in real-world settings. To account for 
uncertainty, we performed a series of sensitivity analyses dem-
onstrating that CrAg screening avoids DALYs for a low cost, 
even with lower risk of CM progression in ART-experienced 
individuals or relatively poor urgent clinical follow-up. We also 
had robust local estimates for most cost and clinical param-
eters, particularly CD4 distribution, CrAg prevalence, and CM 
treatment outcomes data to support our findings14,19. Secondly, 
as a pragmatic study using real-world data, we did not evalu-
ate other screening strategies such as point-of-care CD4 and/or 
CrAg testing, and focused on CrAg screening in clinic settings 
without considering a potential benefit in hospitalized patients34,35. 
Thirdly, our analysis may fail to account for future changes in CD4 
testing practices in Botswana, including a potential shift away 
from CD4 testing as in other settings17. Finally, we limited our 
analysis to CrAg screening in patients with a CD4 count 
<100 cells/µL, reflecting current national guidelines. With the 
WHO recently conditionally recommending CrAg screening 
in individuals with a CD4 count of 100–200 cells/µL6, further 
analysis is needed to model the impact of CrAg screening and 
preemptive therapy in this patient population with a lower 
CrAg prevalence24.
In summary, using local estimates and accounting for uncer-
tainty through sensitivity analyses, we found strong support 
for CrAg screening in Botswana for patients with advanced HIV 
at a threshold of <100 cells/µL. In addition to preemptive ther-
apy in ART-naïve individuals, our findings provide support for 
pre-emptive treatment of CrAg-positive ART-experienced 
patients at a CD4 <100 cells/µL recognized in laboratory-
based reflex CrAg screening programs. Future outcomes data is 
needed for this growing population and guidelines should 
consider the evidence for pre-emptive treatment in this group.
Data availability
Underlying data
Open Science Framework: Cost effectiveness of cryptococcal 
antigen screening in Botswana. https://doi.org/10.17605/OSF.IO/
URXAG23.
This project contains the underlying data used for this mod-
eling study, including a description of all estimates and their 
sources under tab “Screening Parameter Estimates”.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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 place for the programme to succeed and be cost-effective. It is an opportunity to identify possible
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best-case cost-effectiveness that is predicted will prevail.
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